Michael Glodé

1.9k total citations · 1 hit paper
13 papers, 916 citations indexed

About

Michael Glodé is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Michael Glodé has authored 13 papers receiving a total of 916 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Immunology. Recurrent topics in Michael Glodé's work include Immunotherapy and Immune Responses (3 papers), Prostate Cancer Treatment and Research (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Michael Glodé is often cited by papers focused on Immunotherapy and Immune Responses (3 papers), Prostate Cancer Treatment and Research (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Michael Glodé collaborates with scholars based in United States, India and Canada. Michael Glodé's co-authors include A. Rosowsky, Glenn Steele, Emil Frei, Steven E. Come, Vic Raso, William D. Ensminger, David C. Levin, Thomas W. Flaig, Ulka N. Vaishampayan and Wei Du and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Michael Glodé

11 papers receiving 872 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

1978 414 citations William D. Ensminger, A. Rosowsky et al. PubMed profile →

Peers

Michael Glodé

ONCOL

PRM

HEPAT

SURGE

Edwina Baskin-Bey United States

Yong‐Song Guan China

G. Galatola Italy

Munenori Tahara Japan

Biagio Agostara Italy

Yasutaka Shuno Japan

Jiasheng Zheng China

Tatsuya Rikimaru Japan

Samantha M. Ruff United States

Edwina Baskin-Bey United States

Michael Glodé

374 ×0.9

ONCOL

437 ×1.4

PRM

290 ×1.1

HEPAT

292 ×1.4

331 ×1.7

SURGE

Citations per year, relative to Michael Glodé Michael Glodé (= 1×) peers Edwina Baskin-Bey

Countries citing papers authored by Michael Glodé

Since Specialization

Citations

This map shows the geographic impact of Michael Glodé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Glodé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Glodé more than expected).

Fields of papers citing papers by Michael Glodé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Glodé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Glodé. The network helps show where Michael Glodé may publish in the future.

Co-authorship network of co-authors of Michael Glodé

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Glodé. A scholar is included among the top collaborators of Michael Glodé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Glodé. Michael Glodé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Paudel, Bishnu Dutta, et al.. (2019). P1.16-19 Understanding Physician Barriers in the Management of Lung Cancer in Nepal. Can Educational Intervention Make a Difference?. Journal of Thoracic Oncology. 14(10). S594–S594.

Kavanagh, Brian D., Tracey E. Schefter, René González, et al.. (2011). Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiation Oncology. 6(1). 34–34. 114 indexed citations

Kavanagh, Brian D., Tracey E. Schefter, René González, et al.. (2010). Stereotactic Body Radiation Therapy for Melanoma and Renal Cell Carcinoma: Impact of Single Fraction Equivalent Dose on Local Control. International Journal of Radiation Oncology*Biology*Physics. 78(3). S190–S191. 10 indexed citations

Flaig, Thomas W., Michael Glodé, Daniel L. Gustafson, et al.. (2010). A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer. The Prostate. 70(8). 848–855. 148 indexed citations

Attia, Steven, Jens C. Eickhoff, George Wilding, et al.. (2008). Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer. Clinical Cancer Research. 14(8). 2437–2443. 47 indexed citations

Beer, Tomasz M., John M. Corman, Michael Glodé, et al.. (2007). Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). Journal of Clinical Oncology. 25(18_suppl). 5059–5059. 12 indexed citations

Grossman, H. Barton, Catherine M. Tangen, Carlos Cordon‐Cardo, et al.. (2006). Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A southwest oncology group study. Oncology Reports. 16(4). 807–10. 17 indexed citations

Glodé, Michael, Celestia S. Higano, Juergen Meyer, et al.. (2004). A phase I/II trial of CD3/CD28 activated T cells (Xcellerated T Cells) in patients with hormone refractory prostate cancer. Journal of Clinical Oncology. 22(14_suppl). 2549–2549. 1 indexed citations

Whitehead, Robert P., Danika L. Lew, Robert C. Flanigan, et al.. (2002). Phase II Trial of Recombinant Human Interleukin-4 in Patients With Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study. Journal of Immunotherapy. 25(4). 352–358. 39 indexed citations

10.

Vaishampayan, Ulka N., Michael Glodé, Wei Du, et al.. (2000). Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.. PubMed. 6(11). 4205–8. 108 indexed citations

11.

Manni, Andrea, Richard J. Santen, Alice E. Boucher, et al.. (1984). Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation.. PubMed. 4(3). 141–4. 5 indexed citations

12.

Ensminger, William D., A. Rosowsky, Vic Raso, et al.. (1978). A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.. PubMed. 38(11 Pt 1). 3784–92. 414 indexed citations breakdown →

13.

Glodé, Michael, I Scher, & David L. Rosenstreich. (1975). Endotoxin unresponsiveness in C3H/HEJ mice. 34(3). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact